In active AML, outcomes superior for allo-HCT with unrelated donor than for cord blood transplantation
OS longer for premenopausal patients receiving ribociclib in addition to endocrine therapy.
Incidence of all invasive cancers decreased among men aged 20 to 49 years, increased in women.
Elderly, frail receiving 60 percent of oxaliplatin/capecitabine dose have noninferior PFS, less toxicity.
For patients with PD-L1 combined positive score of ≥10, pembrolizumab prolongs overall survival.
Updates include adjuvant radiotherapy for patients with adverse pathologic findings, hormonal therapies.
Perception varies by knowledge of latest recommendations, date of last mammogram.
Findings show radical hysterectomy at high-volume centers tied to better survival in early cervical cancer.
Organization claims guidelines influenced by people with financial ties to Purdue Pharma.
Sexual-minority women with access deficits have increased odds of poor physical, mental quality of life.
Findings based on guideline-based screening for breast, prostate, colorectal cancer.
Significant drop seen in first 10 years of cessation, continues to decrease as cessation time increases.
More marked increases in incidence observed from 2006 to 2013 than from 1973 to 2006.
Increased odds ratios for cancer observed in different categories of OSA for women, not men.
Despite overall decline or stabilization, increase seen for young adults in some high-income countries.